Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scpharmaceuticals Inc.

2.32
-0.1600-6.45%
Post-market: 2.320.00000.00%19:01 EDT
Volume:399.57K
Turnover:938.00K
Market Cap:116.66M
PE:-1.21
High:2.48
Open:2.48
Low:2.29
Close:2.48
Loading ...

scPharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
07 Mar

scPharmaceuticals Says US FDA Approves Application to Expand Use of Furoscix

MT Newswires Live
·
07 Mar

scPharmaceuticals Inc - Furoscix Is Expected to Be Available for Chronic Kidney Disease Patients in April 2025

THOMSON REUTERS
·
07 Mar

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix® Indication to Include the Treatment of Edema in Patients With Chronic Kidney Disease

THOMSON REUTERS
·
07 Mar

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

GlobeNewswire
·
07 Mar

Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know

Zacks
·
06 Mar

ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
05 Mar

ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
03 Mar

scPharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire
·
27 Feb

Shareholders in scPharmaceuticals (NASDAQ:SCPH) have lost 68%, as stock drops 12% this past week

Simply Wall St.
·
24 Feb

TD Cowen Sticks to Their Buy Rating for scPharmaceuticals (SCPH)

TIPRANKS
·
29 Jan

scPharmaceuticals Reports Preliminary Q4 Revenue Of $12M-$12.3M; FY24 Revenue Expected To Be $36.2M-$36.5M

Benzinga
·
10 Jan

scPharmaceuticals Inc Preliminary Unaudited Full Year 2024 Net Revenue Expected to Be Approximately $36.2 Mln to $36.5 Mln

THOMSON REUTERS
·
10 Jan

scPharmaceuticals Inc - Q4 2024 Net Revenue Expected to Be $12M-$12.3M, 99% Growth Over Q4 2023

THOMSON REUTERS
·
10 Jan

Press Release: scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
10 Jan

scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shift From Loss To Profit

Simply Wall St.
·
31 Dec 2024

ScPharmaceuticals Stock Falls After Noting Possible FDA Submission Delay

Dow Jones
·
11 Dec 2024

scPharmaceuticals Inc - Snda Submission for Scp-111 May Be Delayed

THOMSON REUTERS
·
11 Dec 2024

scPharmaceuticals Inc - Observes Variability in Scp-111 Product Testing

THOMSON REUTERS
·
11 Dec 2024